PET Scan Combined With CT Scan in Evaluating Treatment Response in Patients Undergoing Treatment for Bone Cancer or Soft Tissue Sarcoma
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
RATIONALE: Diagnostic procedures, such as PET scan and CT scan, may help doctors determine the extent of cancer and predict a patient's response to treatment and help plan the best treatment.
PURPOSE: This clinical trial is studying how well PET scan combined with CT scan evaluates treatment response in patients undergoing treatment for bone cancer or soft tissue sarcoma.
Condition | Intervention |
---|---|
Sarcoma |
Procedure: computed tomography Procedure: positron emission tomography Procedure: radionuclide imaging Radiation: fludeoxyglucose F 18 |
Study Type: | Interventional |
Study Design: | Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Diagnostic |
Official Title: | Glucose Metabolic Response by PET/CT to Sarcoma Treatments |
- correlating progression-free survival, overall survival, and degree of tumor necrosis at the time of surgery with Glucose metabolic activity, early and late after treatment. [ Designated as safety issue: No ]
Enrollment: | 120 |
Study Start Date: | January 2006 |
Study Completion Date: | October 2011 |
Primary Completion Date: | October 2011 (Final data collection date for primary outcome measure) |
OBJECTIVES:
- Determine whether an FDA-approved device that combines fludeoxyglucose ^18F positron-emission tomography (FDG-PET) and CT scanning (FDG-PET/CT) can accurately locate and determine the extent of disease in patients who are undergoing treatment for bone or soft tissue sarcoma.
- Determine whether FDG-PET/CT scanning is effective in evaluating the response of sarcoma to treatment.
- Determine whether the new FDG-PET/CT device improves the ability to evaluate treatment response early and accurately.
- Correlate changes in glucose metabolic activity early and late after treatment with overall and progression-free survival.
- Correlate changes in glucose metabolic activity early and late after treatment with degree of tumor necrosis at the time of surgery.
OUTLINE: This is a prospective, pilot study. Patients are stratified according to disease (high-grade soft tissue sarcoma vs low-grade soft tissue sarcoma vs osteosarcoma).
Patients undergo fludeoxyglucose ^18F positron-emission tomography (FDG-PET)/CT scanning at baseline and then within 2 weeks and 12 weeks after the start of treatment (total of 3 scans).
PROJECTED ACCRUAL: A total of 120 patients will be accrued for this study.
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Histologically or cytologically confirmed bone or soft tissue sarcoma
- Scheduled to undergo treatment (i.e., chemotherapy and/or radiotherapy) for sarcoma
- Negative pregnancy test
- Fertile patients must use effective contraception
- Not claustrophobic
- Able to lie supine for 1 hour
- Patients with diabetes mellitus allowed provided serum glucose levels ≤ 200 mg/dL
Exclusion Criteria:
- pregnant
- other malignancies within the past 5 years (except completely resected cervical or nonmelanoma skin cancer) unless the malignancy was curatively treated and is at low risk for recurrence
United States, California | |
Jonsson Comprehensive Cancer Center at UCLA | |
Los Angeles, California, United States, 90095-1781 |
Study Chair: | Johannes Czernin, MD | Jonsson Comprehensive Cancer Center |
Additional Information:
No publications provided
Responsible Party: | Jonsson Comprehensive Cancer Center |
ClinicalTrials.gov Identifier: | NCT00335751 History of Changes |
Other Study ID Numbers: | CDR0000480348, P30CA016042, UCLA-0508095-01 |
Study First Received: | June 8, 2006 |
Last Updated: | July 27, 2012 |
Health Authority: | United States: Institutional Review Board |
Keywords provided by Jonsson Comprehensive Cancer Center:
recurrent adult soft tissue sarcoma stage I adult soft tissue sarcoma localized osteosarcoma metastatic osteosarcoma |
recurrent osteosarcoma stage II adult soft tissue sarcoma stage III adult soft tissue sarcoma stage IV adult soft tissue sarcoma |
Additional relevant MeSH terms:
Sarcoma Neoplasms, Connective and Soft Tissue Neoplasms by Histologic Type Neoplasms |
ClinicalTrials.gov processed this record on October 16, 2012